187 related articles for article (PubMed ID: 36578217)
1. HDAC6 regulates human erythroid differentiation through modulation of JAK2 signalling.
Vong P; Messaoudi K; Jankovsky N; Gomilla C; Demont Y; Caulier A; Jedraszak G; Demagny J; Djordjevic S; Boyer T; Marolleau JP; Rochette J; Ouled-Haddou H; Garçon L
J Cell Mol Med; 2023 Jan; 27(2):174-188. PubMed ID: 36578217
[TBL] [Abstract][Full Text] [Related]
2. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Tong W; Zhang J; Lodish HF
Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
[TBL] [Abstract][Full Text] [Related]
3. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
4. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
6. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
[TBL] [Abstract][Full Text] [Related]
7. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Dasmahapatra G; Patel H; Friedberg J; Quayle SN; Jones SS; Grant S
Mol Cancer Ther; 2014 Dec; 13(12):2886-97. PubMed ID: 25239935
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 6 (HDAC6) promotes the pro-survival activity of 14-3-3ζ via deacetylation of lysines within the 14-3-3ζ binding pocket.
Mortenson JB; Heppler LN; Banks CJ; Weerasekara VK; Whited MD; Piccolo SR; Johnson WE; Thompson JW; Andersen JL
J Biol Chem; 2015 May; 290(20):12487-96. PubMed ID: 25770209
[TBL] [Abstract][Full Text] [Related]
10. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
11. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
[TBL] [Abstract][Full Text] [Related]
12. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK/NF-κB pathways.
Zhang WB; Yang F; Wang Y; Jiao FZ; Zhang HY; Wang LW; Gong ZJ
Biomed Pharmacother; 2019 Sep; 117():109166. PubMed ID: 31255993
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts.
Ji P; Yeh V; Ramirez T; Murata-Hori M; Lodish HF
Haematologica; 2010 Dec; 95(12):2013-21. PubMed ID: 20823130
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
Tsuji G; Okiyama N; Villarroel VA; Katz SI
J Allergy Clin Immunol; 2015 May; 135(5):1228-39. PubMed ID: 25458911
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy.
Chen X; Yu C; Hou X; Li J; Li T; Qiu A; Liu N; Zhuang S
Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1003-F1014. PubMed ID: 33103445
[TBL] [Abstract][Full Text] [Related]
17. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
Jochems J; Boulden J; Lee BG; Blendy JA; Jarpe M; Mazitschek R; Van Duzer JH; Jones S; Berton O
Neuropsychopharmacology; 2014 Jan; 39(2):389-400. PubMed ID: 23954848
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
Shi J; Yuan B; Hu W; Lodish H
Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
[TBL] [Abstract][Full Text] [Related]
20. HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells.
Kim JY; Han SY; Yoo J; Kim GW; Jeon YH; Lee SW; Park J; Kwon SH
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
